Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on August 2, 2022. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Request for Information (RFI) for the National Cancer Institute's Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR)

Closed
HHS-NIH-NCI-RFI-MOSB-75N91020R00062-27Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

N/A

Place of Performance

MD

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → NIH Nci
Contacts2 people available
OfficeBethesda, MD, 20892, USA
Office AddressBethesda, MD, 20892, USA
Contacts

Full Description

Show more
I. BACKGROUND: The National Cancer Institute (NCI) is requesting information from all parties who may be interested in the re-competition of the NCI's FFRDC. The FFRDC provides rapid response capabilities and one-of-a-kind resources for the biomedical research community within NCI, NIH and other Federal Agencies. Located in Frederick, MD, the NCI's FFRDC is a Government-Owned Contractor-Operated (GOCO) research facility with a unique array of research support and advanced technologies, whose purpose is to bridge the gaps from discovery to healthcare delivery; to accelerate the development of new technologies and prototype treatments for patients; and to pave the way for new advances to enter clinical trials for testing, approval, and delivery to patients via the commercial sector. Entities authorized to operate, manage, or administer an FFRDC include: a university, a consortium of universities, other not-for-profit or nonprofit organizations, industrial firms as autonomous organizations (identified separately from any parent organization), or industry/academia partnerships. For more information, please refer to the website at http://frederick.cancer.gov/. II. DISCLAIMER TO PROSPECTIVE RESPONDENTS: THIS IS A REQUEST FOR INFORMATION (RFI). This is NOT a solicitation for proposals, capability statements, proposal abstracts, or quotations. The purpose of this RFI is to obtain knowledge and information for project planning purposes. Interested parties are advised that the U.S. Government will not pay for any information or administrative costs incurred in response to this RFI; all costs associated with responding to this RFI will be solely at the interested party's expense. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. Those not responding to this RFI are not prohibited from participation in the RFP. A solicitation has been releasedand synopsized on Sam.gov (SAM) in addition to the NCI Office of Acquisition's website under the FNLCR Acquisition Portal at https://www.cancer.gov/about-nci/contracts/fnlcr-acquisitions/acquisition-notices. Information posted to SAM takes precedence over information provided elsewhere and serves as the Government's official government-wide point of entry (GPE). III. INFORMATION FROM INDUSTRY: The Government is exploring a potential Facilities Site Tour of the NCI-Frederick Campus, the week following the NCI FFRDC Pre-Proposal Conference. To ensure the Government can plan accordingly, interested organizations are asked to respond to the following: Please express if your organization would be interested in attending a 1-day Facilities Site Tour for purposes of proposal preparation? To ensure appropriate health precautions are maintained, please indicate if a 2-3 person limitation, per organization, is sufficient. If not, please provide a rationale for an increase in participants and a recommended number of attendees that would be sufficient for your efforts. IV. DESCRIPTION OF INFORMATION REQUESTED: The due date for the submission of responses to this RFI is 4:00 PM EDT on August 11, 2022. You must submit your response electronically via e-mail and the RFI response must be sent to FNLCR_ACQinfo@nih.gov with subject line - Response to RFI Notice Number: HHS-NIH-NCI-RFI-MOSB-75N91020R00062-27. Any questions related to this RFI should be directed to FNLCR_ACQinfo@nih.gov with the subject line entitled: - Question to RFI Notice Number: HHS-NIH-NCI-RFI-MOSB-75N91020R00062-27. CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use information provided by respondents for any purpose(s) it deems necessary and legally appropriate.

More opportunities from Department Of Health And Human Services → NIH Nci

Same awarding agency

NAICS: 622110
Federal
NCI 2026 Cervical Cancer Screening Follow-Up
Solicitation # NCI-SBSS-DCEG-TDRP-0001
The National Cancer Institute (NCI) has issued a Small Business Sources Sought notice, NCI-SBSS-DCEG-TDRP-0001, to identify qualified small business sources for the 2026 Cervical Cancer Screening Follow-Up project. The primary objective is to obtain de-identified clinical and risk factor history and follow-up data for women previously enrolled in cervical cancer screening studies at Kaiser Permanente Northern California. This data, which includes HPV and cytology-based testing, colposcopy, biopsy, and treatment procedures, will be used to generate long-term risk estimates. The acquisition falls under NAICS code 622110 for General Medical and Surgical Hospitals, with a size standard of 47 million dollars. The anticipated period of performance is five years, spanning from January 25, 2027, to January 24, 2032, consisting of a 12-month base year and four 12-month option years. The selected contractor will be required to deliver five annual data sets in .txt, SAS, or EXCEL formats via NCI-approved secure encrypted methods, ensuring compliance with Section 508 ICT accessibility requirements. Additionally, the contractor must participate in quarterly WebEx meetings to review progress. Interested small businesses, including HUBZone, veteran-owned, 8(a), and woman-owned concerns, must submit a tailored capability statement of no more than five pages to the designated contracting officers by 8:00 AM Eastern Time on October 26, 2026.
General Medical and Surgical Hospitals

POSTED

13 days ago

DEADLINE

in 5 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS